PMC:7402624 / 3988-4744
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 101 | 107-116 | Species | denotes | SARS-CoV2 | Tax:2697049 |
| 102 | 253-261 | Species | denotes | patients | Tax:9606 |
| 103 | 545-553 | Species | denotes | patients | Tax:9606 |
| 104 | 740-747 | Species | denotes | patient | Tax:9606 |
| 105 | 536-544 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T31 | 107-111 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T32 | 536-544 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T47 | 272-273 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T48 | 585-593 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activate |
LitCovid-PD-GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T20 | 87-103 | http://purl.obolibrary.org/obo/GO_0006955 | denotes | immune responses |
| T21 | 146-161 | http://purl.obolibrary.org/obo/GO_0006955 | denotes | immune response |
| T22 | 351-366 | http://purl.obolibrary.org/obo/GO_0006955 | denotes | immune response |
| T23 | 426-442 | http://purl.obolibrary.org/obo/GO_0006955 | denotes | immune responses |
| T24 | 664-679 | http://purl.obolibrary.org/obo/GO_0006955 | denotes | immune response |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T30 | 0-192 | Sentence | denotes | Taken together, this previous work provokes questions about the potential diversity of immune responses to SARS-CoV2 and the relationship of this immune response diversity to clinical disease. |
| T31 | 193-320 | Sentence | denotes | However, many studies describe small cohorts or even single patients, limiting a comprehensive interrogation of this diversity. |
| T32 | 321-500 | Sentence | denotes | The relationship of different immune response features to clinical parameters, as well as the changes in immune responses and clinical disease over time, remain poorly understood. |
| T33 | 501-756 | Sentence | denotes | Because potential therapeutics for COVID-19 patients include approaches to inhibit, activate, or otherwise modulate immune function, it is essential to define the immune response characteristics related to disease features in well-defined patient cohorts. |